75 results about "Stage tumor" patented technology

An early stage tumor localizing tracking based on the multimode sensitization imaging fuse, belongs to the medical image processing field. The invention includes: a medical image before the operation for obtaining the tumour aim focus imaging sensitization; an ultrasound sensitization image during the operation for obtaining the tumour aim focus imaging sensitization. When the image is processed the guide therapy, using the global rigid transformation and the local nonstiff transformation combination round the tumour aim focus as the geometric transformation model with deformation registration, the sensitization images before and during the operation are processed with the deformation registration based on the union marked region, while the images before and during the operation are fused, to rebuild the three-dimensional visualization model in the tumor focus region. Using the above deformation registration method to complete the sport deformation compensation for the imaged before the operation, the target tracking of the tumour target focus is further automatically completed. The invention can be used in a plurality of places, such as the early diagnosis of the tumour, the image guide tumour early intervention, the image guide minimal invasive operation, the image guide physiotherapy etc.

Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

The invention provides a high-specificity and high-sensitivity coordinated antibody against human thymidine kinase 1 (TK1) prepared from an antigenic determinant consisting of 23 peptides at an N terminal, 20 peptides at a C terminal and 28 peptides at the C terminal of the TK1 monomer from a human hela cell and the use of the detection and diagnosis system of the antibody in tumor diagnosis. The antigenic determinant comprises the following amino acid sequences: the sequence of the 23 peptides (3-25) at the N terminal:CINLPTVLPGSPSKTRGQIQVIL; the sequence of the 20 peptides(206-225) at the C terminal: CPVPGKPGEAVAARKLFAPQ; and the sequence of the 28 peptides (198-225) at the C terminal: AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention also provides a method for preparing the antibody by using the antigen. An antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like; and the early tumor can be detected and pre-warned in mass physical examination screening by enhanced chemiluminescence dot blot assay, immuno-histochemistry and the detection kit.

The invention discloses a tumor marker CD25 autoantibody and application of the tumor marker CD25 autoantibody, belonging to the technical field of immunology. The invention provides an amino acid sequence of antigen of immune response regulation gene CD25. The CD25 polypeptide antigen is used for detecting corresponding specific autoantibody in blood of lung cancer and esophageal cancer patients; and the autoantibody can be used as a tumor marker to evaluate risk level of occurrence of lung cancer and esophageal cancer. The antigen polypeptide and the antibody can be used for preparing early-stage tumor diagnostic reagent and developing target drugs for treating tumor.

A method and apparatus for forming and controlling a microwave Bessel beam which may be utilized for examining microstructure including very early stage tumors.

The invention discloses a CT / FT / PET three-mode synchronous imaging device which comprises a horizontally-moving table, a detection bed, a disc-shaped CT machine frame, a PET / FT machine frame, an X-ray tube, an X-ray detector, four PET detection heads, a laser, a CCD camera, an X-ray collimator, a filter wheel and a computer for constructing an image processing platform, wherein the disc-shaped CT machine frame and the PET / FT machine frame rotate with the axis of a detected small animal as the central axis, and each PET detection head is composed of six PET basic detection units. The CT / FT / PET three-mode synchronous imaging device integrates the advantages of the CT imaging mode, the FT imaging mode and the PET mode, more comprehensive and more accurate function and structure information can be provided for small animal carrier research, and the detection performance of early-stage tumors can be greatly improved.

The invention discloses a trans-oligonucleotide probe contrast-medium to mark superparamagnetism iron oxide, which consists of carrier constituted by gluglucosan enveloped by ferroferric oxide nanometer particle with superparamagnetism and trans-oligonucleotide segment of c-erbB2 cancer gene, wherein the trans-oligonucleotide connects the gluglucosan in the carrier at covalent bond. The invention also relates to a making method of the contrast-medium. The invention uses trans-gene technique of molecular biological domain into imaging diagnosis to combine the superiority and specificity of two advanced techniques, which increases the ratio of target / non-target of probe to the maximum degree to scan the size, position and anatomical relationship of adjacent structures of tumour through magnetic resonance, in order to build new imaging method of early-stage tumor diagnosis of specificity on the gene level. The invention can be applied to do early-stage imaging diagnosis for malignant tumour, epoophoron cancer, uterine neck cancer, esophagus cancer and cervical scale cancer.

The invention relates to a preparation method of a CT nano contrast agent namely low-algebraic tree-shaped macromolecule-coated gold nano particles with a liver cancer targeting function. The preparation method comprises the following steps: dissolving LA-PEG-COOH into a solvent, adding EDC to activate the LA-PEG-COOH for 4 to 6 hours, dropwise adding the solution into a G2-FITC solution, stirring to carry out reactions, performing dialysis, and freeze-drying so as to obtain G2-FITC-PEG-LA; dissolving G2-FITC-PEG-LA into distilled water, adding a chloroauric acid water solution, stirring for 10 to 20 minutes, then adding a NaBH4 water solution, stirring to carry out reactions for 2 to 3 hours, performing dialysis, and freeze-drying so as to obtain the target product. The raw materials are cheap, and the gold nano particles which are prepared by taking a low-algebraic tree-shaped macromolecule as the template, has excellent stability and bio-compatibility. The in-vivo blood circulation time of the gold nano particles is prolonged, and moreover the gold nano particles have a specific targeting function on liver cancer cells, so the gold nano particles are advantageously used in the early-stage tumor detection.

The invention provides a stable nanoscale superparamagnetic iron oxide solution which is used as a contrast agent for magnetic resonance imaging (MRI). The superparamagnetic iron oxide solution is characterized in that the particle size of nanoscale superparamagnetic iron oxide particles is stabilized to between 60 and 75 nanometers when the superparamagnetic iron oxide solution is stored for 12 months at an environmental temperature of 4 to 38 DEG C, and the nanoscale superparamagnetic iron oxide particles are in high dispersibility and free from agglomerating or precipitating. After nanoscale superparamagnetic iron oxide solution containing 25mcg of iron, provided by the invention, is subjected to intravenous injection in the MRI of an early-stage in-situ hepatic cancer tumor live model of a rat, the imaging performance of the tumor in the MRI is obviously improved, the position, boundary and size of the tumor can be clearly displayed, and the tumor image effect remains significant after 24 hours; the phenomenon that the boundary and size of the tumor are unclear occurs in the MRI of the early-stage in-situ hepatic cancer tumor live model without contrast agent. Therefore, the nanoscale superparamagnetic iron oxide solution provided by the invention has a stable nanometer solution characteristic, is obvious in tumor impacting effect under low-dosage injection, and unique in innovation and application prospect.

The invention discloses a multi-degree-of-freedom cone-beam CT imaging system in the field of CT imaging technology, which includes: a six-axis mechanical arm, a C-shaped bracket with a translation device, a flat panel detector bracket with a double translation device and a rotation device, and The X-ray light source, wherein: the end of the six-axis mechanical arm is connected to the C-shaped support, and the two ends of the C-shaped support are respectively connected to the flat panel detector support and the X-ray light source. The device involved in the present invention has high flexibility, and can realize multiple scanning modes of cone beam CT axial scanning, helical scanning and non-coplanar scanning, as well as functions such as online real-time adjustment of imaging geometric parameters, and has flexible scanning methods, wide scanning range, With outstanding advantages such as adjustable imaging parameters, it is suitable for applications such as precise intraoperative navigation, adaptive radiation therapy, and early tumor screening and diagnosis.

The invention relates to a preparation method of dyad, particularly relates to a preparation method of targeting porphyrin fluorescent molecule and gold nanorod dyad and solves technical problems that porphyrin fluorescent molecules are prone to gather on the skin and eyes to generate phototoxicity due to poor targeting when the porphyrin fluorescent molecules are transported in bodies and gold nanorods can not stably exist in polar solvents. The method includes preparing a golden seed solution, preparing a gold nanorod growing solution, preparing a polyethylene glycol stabilized gold nanorod solution, preparing the dyad, mixing biomolecules or anticarcinogen and the dyad with N, N-dimethylformamide for reaction, performing centrifugation, dispersing precipitates in methyl alcohol, and then performing separation again to obtain the targeting porphyrin fluorescent molecule and gold nanorod dyad. According to the prepared targeting porphyrin fluorescent molecule and gold nanorod dyad, effects of early-stage tumor diagnosis and treatment can be improved, side effects on normal organizations can be reduced, and the dyad can be connected with biomacromolecules and the anticarcinogen which have targeting actions so that targeting capacity and tumor treatment effects are further improved.

The invention relates to the technical field of radioactive medicinal chemistry and clinic nuclear medicine and particularly relates to a 68Ga marked EGFR targeted tracer agent 68Ga-NOTA-ZEGFR:1907 and a preparation method and application thereof. The molecular imaging probe 68Ga-NOTA-ZEGFR:1907 is specific and targeted to combination of EGFR; a HCC827 hetero-transplanted tumor can be displayed clearly after injection of 30 min, and tumor imaging quality is good in a later period (tumor uptake values are 2.58% ID / g and 2.69% ID / g after injection of 1 h and 2 h respectively); the tumor uptake values are higher than uptake values of most other organs, and satisfactory imaging effects can be obtained; and an autoradiography grey level of 68Ga-NOTA-ZEGFR:1907 in a human tumor tissue specimen is in positive linear correlation with an EGFR expression degree (R2=0.62, P (0.0001).

The invention discloses an establishment method and application of a tumor classification and identification model, belongs to the field of medical disease diagnosis, aims at the problems that samplepreprocessing is complex and time-consuming due to need of location and collection of tumor focus specimens in current pathological diagnosis, small tumor tissues such as early tumor, small residual diseases and circulating tumor cannot be screened diagnosed in the prior art, and provides the establishment method of the tumor classification and identification model. The method is established basedon a plasma emission spectrum of a biological liquid sample, and is combined with chemometrics and a machine learning classification algorithm. The model established through the method can be integrated into a tumor diagnosis and screening instrument, and a rapid and accurate method for large-scale tumor screening and diagnosis of the early tumor and precancerous lesion stage diseases is provided.

Disclosed herein are methods for assessing risk of metastasis of a tumor in a mammal by determining the paxillin gene copy number per cell in the tumor or by detecting the presence of a paxillin mutation in the tumor. The presence of an increased paxillin gene copy number or a paxillin mutation is indicative of an increased risk of metastasis. Methods of staging tumors and methods of reducing invasiveness or metastasis of a cancer cell are also provided. Oligonucleotides comprising a paxillin mutation and antibodies capable of recognizing a paxillin mutant are disclosed.

The invention discloses an application of FOXE1 gene and WNT3 gene as well as a methylation amplimer and a probe of the FOXE1 gene and the WNT3 gene, belonging to the field of biotechnology. The invention provides an application of the FOXE1 gene and / or WNT3 gene as a methylation colorectal cancer tumor marker and a methylation amplimer and a probe of the FOXE1 gene and WNT3 gene. According to the invention, the FOXE1 gene and WNT3 gene can be used as a tumor marker in colorectal cancer, the sensitivity by combining the two methylation tumor markers can reach 79%, the specificity is 59%, and even the sensitivity of the I-stage tumor patient can reach 63.3%, which indicates the feasibility of finding a methylation tumor marker in whole-blood DNA. The methylation amplimer and the probe disclosed by the invention can detect the obvious difference between the FOXE1 gene and the WNT3 gene in the methylation state in a colorectal cancer patient and normal control whole-blood DNA.

A method and apparatus for forming and controlling a microwave Bessel beam which may be utilized for examining microstructure including very early stage tumors.

A computer program product includes multiple microservices for interrogating clinical records according to one or more projects associated with patient datasets obtained from electronic copies of source documents from the clinical records. A first microservice generates a user interface including a first portion displaying source documents and, concurrently, a second portion displaying structured patient data fields organized into categories for entering structured patient data derived from the source documents displayed in the first portion. Categories and their organization are defined by a template and include cancer diagnosis, staging, tumor size, genetic results, and date of recurrence. A second microservice validates abstracted patient data according to validation rules applied to the categories, validation rules being assigned to the projects and performed on the categories as they are populated. A third microservice provides abstraction review performed by an assigned abstractor or an abstraction manager and spans one or more of the projects.

Highly sensitive imaging of diseased tissues such as cancer is attractive because it potentially allows for early tumor detection. One of the problems associated with conventional, low molecular weight imaging probes is the limited tumor: background ratio. To circumvent this, imaging probes were conjugated to polymeric carriers and were surprisingly found to accumulate specifically at cancer sites. This invention describes an innovative targeting strategy for the selective identification of solid tumors by means of polymer-NIR fluorochrome conjugates which accumulate selectively within cancerous tissue relative to normal tissue.

The invention discloses a nano composite material. The nano composite material is characterized by comprising an inner core component and an outer layer component; the inner core component comprises nano particles; the outer layer component is a multi-layer component including at least one of a stabilizing agent, a medical imaging contrast agent, a chemotherapeutic drug and a tumor-specific ligandor antibody; the mass ratio of the inner core component to the outer layer component is 1:10-1:0.5. The nano composite material has ultrasonic response activity and can efficiently convert absorbed ultrasonic waves into reactive oxide species or thermal energy. The invention further discloses a preparation method of the nano composite material and application in an HIFU synergist. The preparationmethod of the nano composite material is simple, easy to implement and beneficial for large-scale production and popularization; when the nano composite material is used for the HIFU synergist, the ablation effect of HIFU on deep lesions can be improved, the treatment effect on early-stage tumors with small size is improved, the tumor boundary can be subjected to iconography locating and identification, and the damage to the normal tissue of the tumor boundary is reduced.

The invention provides a prognosis evaluation system for a prostate cancer patient and application of the prognosis evaluation system, and relates to the technical field of biomedicine. The evaluationsystem includes detecting a system of 14 sets of immune-related signature genes and a PCIPI. The 14 sets comprise: aDC, Angiogensis, CSF1 Response, GRANS, HCK, Lymphocyte-Specific Attractor, Neutrophils, NK CD56 bright cells, NK CD56 dim cells, Macrophages, Pro-inflammatory, Proliferation, Stromal cell, and ZMYND10 Metagene. According to the invention, the defects of the prior art are overcome, the PCIPI is established, and the correlation between the PCIPI and the recurrence-free lifetime (RFS) of a patient, tumor-infiltrated immune cells and mutation load is determined, so that the potential mechanism of immunotherapy drug resistance generation can be explained, and the clinical treatment of the prostate cancer patient can be guided conveniently.

The invention relates to an application of a radix codonopsis pilosulae and radix astragali composition in preparation of a medicine for preventing and treating advanced tumor related symptoms, in particular to an application of a Shenqifuzheng injection in preparation of a medicine for preventing and treating cancer-related fatigue and / or weight loss of an advanced tumor patient.

The invention provides an occult blood detecting kit which comprises a detection reagent and a color developing agent. The detection reagent is prepared from, by mass, 29-35% of ethyl alcohol, 30-36% of absolute alcohol, 31-37% of purified water and 1-5% of hydrogen peroxide. A preparation method of the detection reagent includes the steps of mixing ethyl alcohol, absolute alcohol, purified water and hydrogen peroxide at a normal temperature according to the formula amounts, and evenly stirring the materials to obtain the detection reagent. The color developing agent is guaiac resin. The invention further provides application of the occult blood detecting kit. By means of the kit, people can find the existence signals of tumors with a more-convenient method, higher sensitivity and lower price the first time when early tumors appear. That is, people can find the signals of the early tumors at least 3-10 years earlier.

Disclosed is a Rcr gene sequence with plant favored codon and synthesized DNA molecule which comprises, nucleotide sequence for encoding the polypeptides having Rana catesbeina Rcr protein reactivity, the nucleotide sequence has at least 70% homology with the position No.51-449 nucleotide sequence in the nucleic acid SEQ ID NO.1, the sequence encodes polypeptide of the amino acid sequence represented by SEQ ID NO.2, the invention can be applied to the preparation of medicament for treating early stage tumor transition.

Disclosed herein are methods of treating benign, pre-cancerous, or non- metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developingbenign, pre-cancerous, or non- metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

This invention relates to heparanase polypeptide epitopes that can combine with human MHC-I molecules, and DNA sequences coding the heparanase polypeptide epitopes. The heparanase polypeptide epitopes can combine with human MHC-I molecules to produce heparanase-specific cytotoxic T lymphocytes, which can kill heparanase-positive tumor cells. Therefore, the heparanase polypeptide epitopes can be used as anti-tumor polypeptide drug vaccines.

The invention discloses a traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from lucid ganoderma, entire meconopsis herbs, dicentra spectabilis, Chinese actinidia roots, bat dung, uncaria rhynchophylla, larva chrysomyiae, selaginella tamariscina, ligusticum chuanxiong hort and fingered citron; a preparation method of the traditional Chinese medicine composition comprises the steps of conducting boiling, concentration, microwave treatment and pulverization in sequence, and making the mixture into tablets or capsules or medicinal granules. The traditional Chinese medicine composition can be widely applied to preparation of antineoplastic which is taken orally, by-products of the traditional Chinese medicine composition can be widely applied as skin injury drugs for external use in the oncotherapy process; the traditional Chinese medicine composition can effectively inhibit differentiation of tumor cells, arouse tumor cells in the dormancy period and cooperate with chemoradiotherapy medicine to kill the tumor cells, the recurrence rate after a tumor is cured is lowered, meanwhile, the traditional Chinese medicine composition is prepared from traditional Chinese medicine on the whole, the toxic and side effects are minor, no therapeutic side effect is generated, on the contrary, adverse reaction of a patient, such as emesis, coughing, inappetence and inside and outside skin injury, caused in the chemoradiotherapy process can be effectively alleviated, immunity of the organism is enhanced, generation of a complication is avoided, and the great popularization significance is achieved.

The invention belongs to the technical field of medical devices, and particularly relates to a B-ultrasonic examination device based on canceration targeted positioning for early diagnosis of a breast cancer. According to the B-ultrasonic examination device based on canceration targeted positioning for early diagnosis of the breast cancer, photosensitive substances are guided into early tumors in a targeted mode through cancer targeted positioning, light energy absorbed by the photosensitive substances is converted into heat energy through infrared light irradiation, the temperature of tumor tissues containing the photosensitive substances rises, therefore, the ultrasonic transmission speed is changed, and acoustic impedance of the tissues is the product of density and sound speed; under a condition that the sound speed is changed, the acoustic impedance is changed along with the change of the sound speed, so that the change of echoes is caused, and the echoes are displayed in an ultrasonic image after being detected and processed by the B-ultrasonic examination device based on canceration targeted positioning, so that a B-ultrasonic inspection of early-stage cancer lesions is realized. The B-ultrasonic examination device comprises an ultrasonic detection head with an infrared emission function, an infrared light emission driver, a scanning controller, an ultrasonic receiver, a detector, a digital conversion DSC, an image processor, a display and the like. A powerful tool is provided for early diagnosis of the breast cancer.

Compositions and methods for the diagnosis of lung cancer are disclosed. Such methods are useful to detect early tumors or provide adequate stage / grade information or tumor specificity. Compositions may comprise one or more lung tumor proteins, teins, immunogenic portions thereof, or polynucleotides that encode such portions. Such compositions may be used, for example, to improve lung cancer diagnosis and prognosis and potentially differentiate between NSCLC and SCLC.